Immunitas Presents Phase 1/2a Data Highlighting Anti-Tumor Activity of Novel Immunotherapy IMT-009 at AACR 2026 Annual Meeting April 21, 2026
Sidewinder Therapeutics Announces $137 Million Series B Financing to Advance Precision Bispecific ADCs into Clinical Development for Cancer April 8, 2026
OrbiMed’s Sidewinder slides toward clinic with $137M series B for antibody-drug conjugates April 8, 2026
Newleos Announces Dosing of First Participant inU.K. Phase 1b Study of NTX-1955 in Generalized Anxiety Disorder April 1, 2026
